NCT Number: NCT00000906
Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients
The purpose of this study is to see if it is safe to combine methadone with two HIV protease inhibitors (PIs), ritonavir (RTV) and saquinavir (SQV), in HIV-infected patients not currently taking PIs. This study will measure the interactions between methadone and the PIs.
Methadone is used treat addicts and to treat severe pain. In order to find the safest way to use methadone with PIs, it is important to evaluate how they interact.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
San Francisco Gen Hosp, San Francisco, California, United States
About this study
Methadone is extensively used in the maintenance treatment of addicts and in the management of severe pain. In order to use methadone with HIV protease inhibitors correctly, it is important to evaluate and quantify interactions between the protease inhibitors and methadone.
Patients receive their usual daily dose of methadone followed with ritonavir and saquinavir, respectively, twice a day. Patients are evaluated on Day 4 for safety and tolerance, and their ritonavir dose is increased. On Day 8 patients are evaluated for a steady-state level of methadone. After 2 weeks of the protease inhibitor therapy, they return for methadone pharmacokinetic sampling at Day 15 over 24 hours. Both protease inhibitors and methadone are administered on Day 15 on an inpatient basis. On Day 30, patients are assessed for safety and tolerance.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
You may be eligible for this study if you:
- Are HIV-positive and have an HIV RNA count below 100,000 copies/ml within 30 days prior to study entry.
- Are taking methadone.
- Are at least 18 years old.
- Are within 40% of your ideal body weight and weigh at least 99 lbs.
Exclusion criteria
You will not be eligible for this study if you:
- Are allergic to or are unable to take RTV or SQV.
- Have a history of treatment failure with indinavir, RTV, or SQV.
- Have a history of certain illnesses that might prevent you from completing the study.
- Have severe diarrhea or other stomach problems.
- Have taken any PI within 4 weeks prior to study entry.
- Would be unable to complete the study due to alcohol or drug abuse.
- Are co-enrolled in other protocols that have you taking medications that are prohibited in this study.
- Are taking PIs other than RTV or SQV.
- Are receiving certain therapies or are taking certain medications, including experimental drugs.
- Have an active opportunistic (AIDS-related) infection or disease that requires medication within 14 days prior to study entry.
- Are pregnant or breast-feeding.
Treatment and study plan
Saquinavir
DrugMethadone Hydrochloride
DrugSponsors and collaborators
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Nih
Registry information
Official study title
The Effect of HIV Protease Inhibitors on the Stereospecific Metabolism of Methadone in HIV-Infected Subjects
Important dates
- Study completion
- 2000
- First posted
- Aug 31, 2001
- Registry last updated
- Nov 4, 2021
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
NCT05378399
Adherence, Medication, Adherence, Treatment
Boston, Massachusetts, United States
View Trial DetailsHIV Engagement and Adolescent Depression Support (HEADS-UP)
NCT06173544
Adolescent Behavior, Anxiety
Lilongwe, Malawi
View Trial DetailsMobile Enhanced Prevention Support for People Leaving Jail
NCT04036396
Bacterial Infections, Bacterial Infections and Mycoses
Los Angeles, California, United States
View Trial DetailsPlanning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care
NCT05925374
Behavior, Blood-Borne Infections
Detroit, Michigan, United States
View Trial Details